OncLive.com· @OncLive · X·· 22 hours agoScore70
Body · original
💥 Survival was improved with durvalumab plus enfortumab vedotin in patients with MIBC according to new data from the phase 3 VOLGA trial
Full details ➡️: https://www.onclive.com/view/durvalumab-plus-enfortumab-vedotin-improves-survival-in-cisplatin-ineligible-mibc
#oncology #blcsm #ESMO26 @myESMO
164 views · 0 likes · 2 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: OncLive.com · x.com